Loading
Precipio, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 10 Apr 2026.
Precipio, Inc.: what insiders have been doing
Precipio, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Over the twelve months to 18 October 2026, the company's managers filed 14 filings, from 5 insiders.
The flow runs one way only: 1 insider bought (4 purchases totalling €1,703) and nobody sold on the market. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Biggest ticket of the year: €458, bought by Sabet Ahmed Zaki and made public on 10 April 2026. The buyers include 1 senior executive.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 14 filings, this issuer sits below that mark. Over the whole record (from 2016), the tally stands at 28 purchases and 7 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 24.0 m USD and net income at -363,000 USD.
The most recent open-market purchase was published on 10 April 2026, 191 days ago. The median gap between a trade and its publication by SEC (Form 4) is 5 days. Section 16 rules allow two business days to file each Form 4.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
89
Thresholds
n/a
Buy Volume
€114,922
28 ops. · all time
Sell Volume
€626,979
7 ops. · all time
Who traded when
BuySaleRichard A. Sandberg5 buys4 sales
Ahmed Zaki Sabet5 buys
Kathleen Laporte1 sale
Since the insiders bought
- -23.8%Entry US$28.05 · Close 16 Oct 2026 US$21.38
- +106.7%Entry US$10.90 · Close at T+365 US$22.53
- -54.2%Entry US$30.60 · Close at T+365 US$14.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,818 of 24,148 companies
32.4
score / 100
Value28
Quality37
FCF yld0.9%
Earn yld-0.9%
EV/EBITDA28.7x
ROE-9.0%
Gross mgn45%
Net mgn-1.5%
Debt/EBITDA2.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$21.38
Analyst consensus
Income statement
RevenueUS$24M
Gross profitUS$10.7M45% margin
EBITDAUS$1.5M6% margin
Net income-US$363k-4.5% margin
Valuation
P/Book2.6x
Beta1.30
Balance sheet & cash
Market capUS$38.3M
Total debtUS$3.7M
Free Cash FlowUS$359k
Debt / Equity24%
Profitability & ownership
ROE-9.0%
ROA-4.8%
% insiders12.6%
% institutions17.7%
Last declaration on 16 July 2026
Declarations89 total
520 shares@ US$25.240.031% mcap2.4% of flowCommon StockSEC:0001104659-26-084263:0
416 shares@ US$25.240.024% mcap7.3% of flowCommon StockSEC:0001104659-26-084266:0
108 shares@ US$25.240.0064% mcap5.9% of flowCommon StockSEC:0001104659-26-084267:0
445 shares@ US$29.490.028% mcap2.3% of flowCommon StockSEC:0001104659-26-044950:0
365 shares@ US$29.490.023% mcap7.2% of flowCommon StockSEC:0001104659-26-044951:0
93 shares@ US$29.490.0058% mcap5.8% of flowCommon StockSEC:0001104659-26-044959:0
19 shares@ US$27.939.7% of flowCommon StockSEC:0001104659-26-041954:0
Canonical exit: 30 Jun 2026 (T+90)
406 shares@ US$24.0020.8% of flowCommon StockSEC:0001104659-26-005039:0
546 shares@ US$24.002.3% of flowCommon StockSEC:0001104659-26-005047:0
437 shares@ US$24.007.1% of flowCommon StockSEC:0001104659-26-005045:0
520 shares@ US$24.005.4% of flowCommon StockSEC:0001104659-26-005043:0
20 shares@ US$23.408.4% of flowCommon StockSEC:0001104659-26-001356:0
Canonical exit: 2 Apr 2026 (T+90)
25 shares@ US$19.508.8% of flowCommon StockSEC:0001104659-25-114690:0
Canonical exit: 30 Dec 2025 (T+90)
31 shares@ US$16.309.1% of flowCommon StockSEC:0001104659-25-114689:0
Canonical exit: 6 Oct 2025 (T+90)
711 shares@ US$17.585.4% of flowCommon StockSEC:0001104659-25-100109:0
597 shares@ US$17.587.1% of flowCommon StockSEC:0001104659-25-100108:0
746 shares@ US$17.582.3% of flowCommon StockSEC:0001104659-25-100107:0
568 shares@ US$17.5811.6% of flowCommon StockSEC:0001104659-25-100104:0
6,152 shares@ US$20.0652.8% of flowCommon StockSEC:0001104659-25-089066:0
710 shares@ US$14.787.2% of flowCommon StockSEC:0001104659-25-069085:0
676 shares@ US$14.7811.6% of flowCommon StockSEC:0001104659-25-069057:0
888 shares@ US$14.782.3% of flowCommon StockSEC:0001104659-25-069055:0
8 shares@ US$9.440.0% of flowCommon StockSEC:0001104659-25-054912:0
Canonical exit: 28 Aug 2025 (T+90)
101 shares@ US$9.800.3% of flowCommon StockSEC:0001104659-25-053598:0
Canonical exit: 25 Aug 2025 (T+90)
500 shares@ US$9.331.3% of flowCommon StockSEC:0001104659-25-052964:0
Canonical exit: 20 Aug 2025 (T+90)
25 of 89 declarations
About Precipio, Inc.
Precipio, Inc. (ticker: PRPO) is a United States-based healthcare biotechnology and diagnostics company listed on the NASDAQ Capital Market. For French-, Belgian- and Swiss-based investors, Precipio is best understood as a small-cap specialty diagnostics platform focused on cancer testing, with particular emphasis on hematologic malignancies and the reduction of misdiagnosis. The company was incorporated in Delaware in 1997 and later took its current form after a reverse-merger transaction in 2017. Its headquarters are in New Haven, Connecticut, placing it in a strong academic and medical ecosystem that supports clinical partnerships and product validation.
Precipio’s business model is built around two complementary activities operating under a single reportable segment. First, the company runs pathology and diagnostic services for physicians, hospitals, and laboratories. Second, it develops and commercializes proprietary diagnostic products and reagents. Management describes this integrated structure as a way to make the service business also function as a self-funded R&D engine: clinical operations generate real-world diagnostic data, while the company uses that environment to refine, validate, and commercialize new products. Precipio operates CLIA-compliant laboratories in New Haven, Connecticut and Omaha, Nebraska, and its product-development work is centered on improving the accuracy and speed of cancer diagnostics.
Read moreShow less
Key offerings include HemeScreen, IV-Cell, and related reagent and panel solutions designed for hematology and oncology workflows. These products aim to improve diagnostic precision, shorten turnaround times, and help clinicians identify blood cancers and related abnormalities more reliably. In competitive terms, Precipio occupies a niche position in a market dominated by much larger diversified diagnostics groups and other specialized lab companies. Its differentiation comes from its focus on misdiagnosis reduction, its proprietary technologies, and its collaboration-oriented operating model. The company has also referenced long-standing academic and medical relationships that support product development and market credibility.
Geographically, Precipio remains primarily U.S.-focused, serving a nationwide customer base from its Connecticut and Nebraska facilities. Recent disclosures indicate a business that is still small but showing operating momentum. In its first-quarter 2026 release, Precipio reported revenue of $6.71 million, while third-quarter 2025 results had already shown year-over-year revenue growth and positive adjusted EBITDA. That said, the company remains execution-sensitive: growth depends on pathology volume, customer onboarding, reimbursement dynamics, and continued adoption of its product line. For investors, Precipio is a specialized NASDAQ-listed U.S. healthcare story with higher risk than large-cap diagnostics peers, but also with a focused niche strategy and potential operating leverage if commercialization continues to scale.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
